Aktienanalyse zu Enanta Pharmaceuticals Inc (ENTA)ENTAEnanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Enanta Pharmaceuticals Inc is a good buy right now due to its recent positive developments, including a significant analyst price target of $20, which represents a potential upside of 47.06% from the current price of $13.6. Additionally, the company has a gross margin of 100%, indicating strong profitability potential despite current losses. The main risk is the recent court ruling against Enanta in a patent dispute, which could impact its competitive position.

4 analysts cover ENTA: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 18.50.